The content is available as a PDF (307.6 KB).
Timing of Rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
Luca Quartuccio
Elena Treppo
Marco Binutti
Giulia Del Frate
Salvatore De Vita
Corresponding author: Luca Quartuccio, M.D., Ph.D., Rheumatology Clinic, Department of Medicine (DAME) University of Udine, ASUFC, Udine, Italy. Email to luca.quartuccio@uniud.it
Received 2021 Feb 3; Revised 2021 Feb 11; Accepted 2021 Feb 15.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)